title: Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia.
abstract: OBJECTIVE
  We investigated effects of changing from oral estrogen to transdermal estradiol on the lipid and lipoprotein profile of postmenopausal women who developed hypertriglyceridemia (serum concentrations exceeding 150 mg/dL) during estrogen-progestin therapy.
  
  
  METHODS
  Sixty-one postmenopausal Japanese women receiving 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate daily for 12 months had developed serum triglyceride concentrations exceeding 150 mg/dL after 12 months of treatment. Thirty-six of them, chosen randomly for study, were assigned at random to either a group that continued this oral regimen or another that changed to transdermal estradiol while continuing 2.5 mg of oral medroxyprogesterone acetate for the next 3 months (n = 18 for each). Blood lipids were compared between groups.
  
  
  RESULTS
  Serum concentrations of triglyceride and very-low-density lipoprotein triglyceride decreased significantly after changing to transdermal estradiol (triglyceride, from 226.0 +/- 43.9 to 110.5 +/- 44.1 mg/dL, P < 0.01). No changes were seen in concentrations of low-density lipoprotein cholesterol or high-density lipoprotein cholesterol.
  
  
  CONCLUSIONS
  Changing to transdermal estradiol may improve triglyceride metabolism in women who developed hypertriglyceridemia during oral estrogen-progestin therapy, with minimal effect on cholesterol profiles.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Hiroshima University, Hiroshima, Japan. msanada64@hotmail.com
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Sanada
authors.forename: Mikio
authors.initials: M
authors.lastname: Tsuda
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kodama
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Sakashita
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Koso
authors.initials: K
authors.lastname: Ohama
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D001053:Apolipoproteins / Q000097:blood / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000517:prevention & control*; D008055:Lipids / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D017698:Postmenopause; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D004958:Estradiol; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate